PainReform Ltd (PRFX): Price-to-Sales Ratio

Corporate company logo of PainReform Limited (PRFX)

Despite its Israeli origin and associated geopolitical risks, PainReform Ltd. (PRFX) maintains stability through global partnerships. High demand for the PRF-110 oil-based formulation provides the company with pricing power in anesthesiology. The price-to-sales ratio on this GURU.Markets platform chart confirms market expectations, where the 0.80 mark serves as a key metric. This reinforces the commercialization potential of non-opioid analgesics and the developer's clinical successes.

P/S Multiple: PainReform (PRFX) for 03/28/2026 - 11/13/2026

Metric breakdowns and analytics for PainReform Limited (PRFX)

- share price and consensus valuation forecast:
Price Performance Chart painreform.com|PRFX - Price Target Chart
- stock exchange capitalization data:
Market Valuation PainReform Limited|PRFX - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share PainReform|PRFX - Book Capitalization|Market Capitalization to Book Value painreform.com|PRFX - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Ratio PainReform Ltd.|PRFX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital PainReform Corp|PRFX - Company Aggregate Debts|Debts to Book Value PainReform Limited|PRFX - Company Long-Term Debts|Current Liabilities PainReform|Immediate Liquidity painreform.com
- company profitability and valuation multiples indicators:
PRFX - Company Net Income|Expected Net Income PainReform Ltd.|PRFX - Price to Earnings Ratio|Projected Price to Earnings PainReform Ltd|PRFX - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation PainReform Limited|PRFX - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months PainReform|PRFX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months painreform.com|PRFX - Earnings growth in current year|Projected earnings per share growth rate for next year PainReform Ltd.
- issuer revenue and sales details:
PRFX - Company Sales|Company Future Sales painreform.com|PRFX - Price-to-Revenue Ratio|Future Price to Revenue PainReform Limited
General company analysis:PRFX - painreform.com
Manufactured products of PainReform Corp

The P/S multiple compares the current market capitalization of PainReform Ltd. (PRFX) to its annual revenue, determining the value of each unit of sales. By analyzing P/S volatility, an investor assesses business transparency, where the potential for implementing innovative PRF-110 analgesics to reduce opioid dependence directly impacts the market revaluation of assets and price action.

Competing companies

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue KVUE|VRNA (Verona Pharma PLC) - Price-to-Sales Ratio|Jyong Biotech Corp - P/S Multiple|LGND - P/S Multiple|AMRX: P/S Multiple|PRGO - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Alvotech SA|Market Cap to Revenue Ratio LQDA (Liquidia Corp)|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP (ANI Pharmaceuticals Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple MNKD (MannKind Corporation)|amphastar.com (AMPH) - Price to Sales|Pacira BioSciences, Inc. - P/S Multiple|Price-to-Sales Ratio SPRY|Theravance (TBPH) - Price-to-Revenue Ratio|Price to Sales Aquestive Corp (AQST)|Price-to-Revenue Ratio scPharmaceuticals, Inc.|TECX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Tonix Pharmaceuticals Holding Corp. (TNXP)|Market Cap to Revenue sxtchina.com SXTC|Eupraxia Pharmaceuticals Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio BHST|EXOZ - Price-to-Revenue Ratio|ORMP: Price-to-Revenue Ratio|ENTX (enterabio.com) - Market Cap to Revenue|HYFT: Market Cap to Sales Volume|ABVC (ABVC BioPharma Inc) - P/S Multiple|Market Cap to Revenue Ratio CPIX (Cumberland Corp)|Market Cap to Revenue QNTM (Quantum BioPharma Ltd)|Price-to-Revenue Coefficient fibrogen.com|Price-to-Revenue Ratio Telomir Pharmaceuticals, Inc. TELO|RANI (Rani Therapeutics Holdings) - Price-to-Sales Ratio|SNYR - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio RLYB (Rallybio Corporation)|LEXX: P/S Multiple|Price-to-Sales Ratio PULM (pulmatrix.com)|Market Cap to Revenue PTHL|Market Cap to Revenue Ratio APM (Aptorum)|Price-to-Revenue Ratio Lyra Therapeutics, Inc (LYRA)|IBO: Price-to-Sales Ratio|P/S Multiple TNFA (TNF Pharmaceuticals, Inc.)|Market Capitalization-to-Revenue Ratio YCBD|Auris Medical - P/S Multiple|LIPO - P/S Multiple|Optinose (OPTN) - Price-to-Revenue Ratio|Pieris Pharma - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Procaps Group S.A.|Market Cap to Revenue petrospharma.com (PTPI)|P/S Multiple QLI|P/S Multiple Acelyrin Inc. (SLRN)|TFF Pharma - Market Cap to Revenue